Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced Metastatic NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT04923945
What this trial is testing

Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung Cancer Metastatic
Hutchison Medipharma Limited 203
Testing effectiveness (Phase 2)Study completedNCT02917993
What this trial is testing

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Incyte Corporation 59
Early research (Phase 1)Looking for participantsNCT06999187
What this trial is testing

DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Who this might be right for
Triple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung Cancer+9 more
Dren Bio 96
Not applicableActive Not RecruitingNCT05103605
What this trial is testing

Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 274
Early research (Phase 1)Ended earlyNCT05061537
What this trial is testing

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Who this might be right for
Renal Cell CancerMelanomaNon-Small-Cell Lung Cancer+7 more
Pfizer 13
Large-scale testing (Phase 3)Looking for participantsNCT07174908
What this trial is testing

IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

Who this might be right for
Non-Small Cell Lung Cancer
InxMed (Shanghai) Co., Ltd. 400
Not applicableNot Yet RecruitingNCT06786208
What this trial is testing

Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

Who this might be right for
Non Small Cell Lung Cancer
Henan Cancer Hospital 55
Early research (Phase 1)Study completedNCT00010023
What this trial is testing

Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Cancer
NYU Langone Health
Large-scale testing (Phase 3)Not Yet RecruitingNCT07829549
What this trial is testing

Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Who this might be right for
Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations
RemeGen Co., Ltd. 540
Testing effectiveness (Phase 2)Ended earlyNCT05275478
What this trial is testing

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Who this might be right for
Locally Advanced Solid Tumor
Tango Therapeutics, Inc. 110
Early research (Phase 1)Ended earlyNCT02387125
What this trial is testing

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Who this might be right for
SarcomaMelanomaNon-small Cell Lung Cancer+1 more
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 79
Testing effectiveness (Phase 2)Study completedNCT05014815
What this trial is testing

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)Nonsmall Cell Lung Cancer, Stage IIIBNonsmall Cell Lung Cancer, Stage IV
BeiGene 272
Testing effectiveness (Phase 2)Study completedNCT00867009
What this trial is testing

Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Cancer
Eli Lilly and Company 113
Testing effectiveness (Phase 2)Looking for participantsNCT07231068
What this trial is testing

A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation

Who this might be right for
Non-Small Cell Lung Cancer
Henan Genuine Biotech Co., Ltd. 153
Testing effectiveness (Phase 2)Looking for participantsNCT05442060
What this trial is testing

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
OBI Pharma, Inc 60
Large-scale testing (Phase 3)Study completedNCT02296125
What this trial is testing

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AstraZeneca 674
Large-scale testing (Phase 3)UnknownNCT03849768
What this trial is testing

Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Who this might be right for
Non Small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 429
Testing effectiveness (Phase 2)Study completedNCT01204697
What this trial is testing

Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 74
Testing effectiveness (Phase 2)Looking for participantsNCT07058519
What this trial is testing

Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

Who this might be right for
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
Shanghai Chest Hospital 250
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 884
Next Page